Aerie Pharmaceuticals Inc. (NASDAQ:AERI) shares saw strong trading volume on Friday . 1,046,465 shares were traded during mid-day trading, an increase of 141% from the previous session’s volume of 434,181 shares.The stock last traded at $18.20 and had previously closed at $17.91.

Several equities research analysts recently weighed in on the company. Zacks Investment Research upgraded Aerie Pharmaceuticals from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a report on Wednesday, April 20th. Brean Capital restated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Monday, May 16th. Finally, Canaccord Genuity restated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Tuesday, May 3rd. Eight investment analysts have rated the stock with a buy rating, Aerie Pharmaceuticals has an average rating of “Buy” and an average price target of $42.50.

The firm’s market capitalization is $481.22 million. The company has a 50-day moving average price of $17.93 and a 200 day moving average price of $16.12.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings results on Monday, May 2nd. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by $0.08. Equities research analysts anticipate that Aerie Pharmaceuticals Inc. will post ($2.69) EPS for the current year.

A hedge fund recently raised its stake in Aerie Pharmaceuticals stock. Schroder Investment Management Group boosted its position in Aerie Pharmaceuticals Inc. (NASDAQ:AERI) by 12.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 471,000 shares of the company’s stock after buying an additional 51,500 shares during the period. Schroder Investment Management Group owned 1.79% of Aerie Pharmaceuticals worth $11,469,000 as of its most recent SEC filing.

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.